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Introduction
The incidence of acute pancreatitis (AP), an inflammatory disorder of the pancreas, has increased in recent years (Pandol et al., 2007; Yadav and Lowenfels, 2013) . To date, no specific therapy has been shown to be effective for AP, which has a high morbidity and mortality (Lankisch, 2015; Forsmark et al., 2016) . Although the molecular mechanism of AP remains unclear, the premature activation of zymogens within the pancreatic acinar cells (PACs) initiates acinar cell injury, which triggers a local and systemic inflammatory response in which the immune cells play a central role (Halangk et al., 2000) . Importantly, PAC itself produces inflammatory mediators, and subsequently, these signals activate immune cells. If this inflammatory reaction is manifest continually, it leads to a systemic inflammatory response syndrome (SIRS) and multiple organ failure (Leung and Ip, 2006) . Accumulating evidence has shown that PI3K, Akt, NF-κB and inflammasome are involved in the pathophysiological process of AP and inhibition of NF-κB and inflammasome can attenuate the severity of AP (Algül et al., 2007; Baumann et al., 2007; Hoque et al., 2011; Huang et al., 2013; Wei et al., 2015) . Furthermore, an endogenous antiinflammatory system is also activated during AP. However, the mechanism of this anti-inflammatory system is still unclear.
Dopamine, one of the most important neurotransmitters, can regulate movement, emotion and cognition in humans (Basu and Dasgupta, 2000) . Dopamine receptors are a superfamily of GPCRs, and are classified into two subtypes, D 1 -like ( D 1 and D 5 receptors) and D 2 -like ( D 2 , D 3 and D 4 receptors), based on their ability to stimulate or inhibit AC respectively. Recent studies have shown that dopamine has multiple anti-inflammatory effects (Wei et al., 2013; Yan et al., 2015; Zhang et al., 2015b) . However, D 1 -like and D 2 -like receptor signalling can act through different mechanisms. Yan and colleagues showed that D 1 receptor signalling can control the processing and secretion of IL-1β and IL-18 in both systemic and periphery inflammation by inhibiting the NLRP3 inflammasome (Yan et al., 2015) . Furthermore, Shao and colleagues found that Drd2 knockout mice show a remarkable inflammatory response in the brain through aBcrystallin (CRYAB)-dependent mechanism (Wei et al., 2013) . In addition, the D 2 receptor has protective effects in the kidney by limiting the inflammatory reaction and an impairing the function of the D 2 receptor results in renal inflammation and organ damage (Zhang et al., 2015b) . Taken together, these results suggest that the dopaminergic system may act as an endogenous anti-inflammatory system retained during evolution.
Notably, the pancreas is an important source of nonneuronal dopamine in the body, and this dopamine has an important role in protecting the pancreas and intestinal mucosa, but its role and the exact molecular mechanism involved in the pancreas is still unclear (Mezey et al., 1996) . Previous studies showed that dopamine is an effective treatment for experimental AP, as a result of its ability to reduce pancreatic microvascular permeability (Karanjia et al., 1991; Karanjia et al., 1994) . However, the role of the pancreatic dopaminergic system in the pathogenesis of AP remains unclear. Therefore, we sought to investigate the role of the dopamine signalling pathway in the inflammatory response during experimental pancreatitis. We investigated the changes in the pancreatic dopaminergic system and the effects of dopamine, D 1 and D 2 agonists and antagonists and pancreatic specific knockout of Drd2 on inflammatory responses in an in vivo and in vitro model of experimental pancreatitis. We showed that the pancreas dopaminergic system is activated, but the expression of D 1 and D 2 receptors is decreased in experimental pancreatitis, suggesting a downregulation of these receptors limits the protective effects of dopamine on AP. Our data also demonstrated that D 2 receptor-mediated signalling controls pancreatic inflammation in AP at least in part through inhibiting NF-κB activation via a serine/threonine protein phosphatase 2A (PP2A)-dependent Akt signalling pathway.
Methods

Patients with AP
Of the patients who were admitted to the Gastroenterology Department of Shanghai General Hospital from November 2014 to August 2015, only those who met the diagnostic criteria of AP were included in the study (Kinns, 2013) . Patients with chronic or other acute inflammatory diseases were excluded. The severity of AP was assessed according to the revised Atlanta criteria . Healthy volunteers were assessed as the control group. The entire study design and procedures involved were in accordance with the Declaration of Helsinki. Informed written consent was obtained from all AP patients and healthy volunteers. The study protocol was approved by the medical ethics committee of Shanghai General Hospital (2017KY170). The methods regarding human subjects were carried out in accordance with approved guidelines and regulations.
Mouse strains
Mice including wild-type (WT) Balb/C, C57BL6/J (6-8 weeks, 20-22 g, male) were purchased from Shanghai SLAC Laboratory Animal Co Ltd (Shanghai, China ). All mice were housed under specific-pathogen-free conditions in individually-ventilated cages with wood shavings as bedding material (4-6 mice per cage), 12 h dark/light cycle at 22°C and free access to water and standard rodent diet. All mice (20-22 g, male) were marked with an earmark and a randomized table was used; they were allocated into groups in a completely randomized manner (n = 6 per group). The pathologists but not to the experimental operators were blinded to the experiment groups. All the experiments involving animals were conducted under the principle for replacement, refinement and reduction (the 3Rs) and according to the legislation on the protection of animals and were approved by the Animal Ethics Committee of Shanghai BJP X Han et al.
Jiaotong University School of Medicine (SYXK 2013-0050, Shanghai, China) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Induction of experimental pancreatitis and treatments
Two murine models of AP have been in use for several years: caerulein-induced AP and L-arginine-induced AP, both are noninvasive and rapidly induced. In caerulein-induced AP the degree of AP severity can be easily controlled and it is highly reproducible; this was developed in mice (20-22 g) by 10 injections of caerulein (100 μg·kg À1 , i.p. with a 1 h interval between injections); LPS (5 mg·kg À1 ) was administered by i.p. injection immediately after the last injection of caerulein, as described previously (Hu et al., 2011; Lerch and Gorelick, 2013; Wu et al., 2016) . L-Arginine-induced AP was initiated in mice (20-22 g) by administration of two i.p. injections of L-arginine (8%, pH = 7.0), each at concentrations of 4 g·kg À1 body weight with a 1 h interval between injections.
L-Arginine induces toxic effects specific to the pancreas (Dawra et al., 2007; Hu et al., 2011; Wu et al., 2016) . Controls received similar injections of normal saline (NS) instead of caerulein or L-arginine. In the caerulein-induced AP model, the first NS injection was defined as 0 h. In the L-arginineinduced AP model, the second NS injection was defined as day 0. Dopamine (50 mg·kg À1 , corresponding to~5% of the median lethal dose -LD 50 ) was administered i.p. at the same time as caerulein, due to its short half-life period (Zaroslinski et al., 1977; Rouge-Pont et al., 2002) . To determine which subtype of dopamine receptor is involved in the effect of dopamine on AP, three experiments in vivo were conducted. Firstly, the AP model was induced by caerulein and LPS in Balb/C mice and a D 1 receptor antagonist SCH-23390 (SCH; 10 mg·kg À1 , i.p., 0.5 h before the first caerulein injection) or D 2 receptor antagonist eticlopride (10 mg·kg À1 , i.p., 0.5 h before the first caerulein injection) was used in combination with the i.p. dopamine, as described in Figure 2C . Secondly, the AP model was induced by caerulein and LPS in Balb/C mice; a D 2 agonist quinpirole (10 mg·kg À1 , i.p., 0.5 h before the first caerulein injection) was used instead of dopamine. Thirdly, the AP model was induced by caerulein and LPS in WT C57BL6/J and in pancreas-specific Drd2 À/À mice on a C57BL6/J background.
Finally, to investigate the molecular mechanisms of D 2 receptor signalling in AP, okadaic acid (100 ng per mouse), a PP2A inhibitor, was administered i.p. 1 h before the first caerulein injection, and quinpirole was administered 0.5 h before first caerulein injection, as described in Figure 7A , B. Animals were killed by exsanguination at the time points indicated in the figures after being anaesthetized with pentobarbital. The histology of pancreatic tissue was quantified on sections stained with haematoxylin-eosin (H&E), which was scored by two experienced pathologists (Van Laethem et al., 1995; Hu et al., 2011) .
Serological test
Blood samples from each group were centrifuged at 400× g for 20 min at 4°C. The serum levels of amylase and lipase were measured by enzyme dynamics chemistry using commercial kits according to the manufacturer's protocols in a Roche/Hitachi modular analytics system (Roche, Basel, Switzerland 
Isolation of pancreatic acinar cells and treatments
PACs were isolated from the pancreas of Balb/C mice using a collagenase (Sigma, USA) digestion procedure as described previously (Gukovskaya et al., 1997; Hu et al., 2011) . PACs were incubated at 37°C in DMEM F-12 medium containing 10% FBS. PACs were then stimulated with 200 nM cholecystokinin (CCK) 8 and treated with dopamine (250, 500 and 750 μM) at the same time. To determine which receptor was involved in the effect of dopamine on CCK-stimulated PACs, two in vitro experiments were conducted. Firstly, the D 1 antagonist SCH (10 μM) or D 2 antagonist eticlopride (10 μM) was used in combination with dopamine (500 μM) at the time of CCK stimulation. Secondly, the D 2 agonist quinpirole (5 μM) was used instead of dopamine (500 μM) at the time of CCK stimulation. Finally, to investigate the molecular mechanisms of D 2 signalling, okadaic acid (2 nM) was administered 15 min before quinpirole (5 μM) and quinpirole was administered at the same time as CCK. PACs were collected at the time points indicated in the Figure  legends .
Western blotting
Total protein of PACs and pancreatic tissues were extracted as described previously (Hu et al., 2011) . Proteins (40 μg per lane) were separated by 10% SDS-PAGE and electrotransferred to normal control membranes (Millipore, USA). Membranes were incubated with primary antibodies against polyclonal tyrosine hydroxylase (1:1000), dopa decarboxylase (DDC; 1:400), dopamine β-hydroxylase (DBH; 1:400), MAO (1:1000), D 2 receptor (1:400), p-PI3K (1:1000), IKK (1:1000), PPP2R2C (1:1000), IL-1β (1:1000) and IL-6 (1:1000); monoclonal PI3K (1:1000), Akt (1:1000), p-Akt (1:1000), p-IKK (1:1000), IκBα (1:1000), p-IκBα (1:1000), NF-κBp65 (1:1000), p-NF-κBp65 (1:1000), PP2A-C (1:1000), TNFα (1:1000) and β-actin (1:1000) overnight at 4°C. After being washed with 0.1% Tween PBS three times, the membranes were probed with goat anti-mouse or goat anti-rabbit IR-Dye 700 or 800 cw labelled secondary antisera for 1 h at 37°C. Membranes were imaged with an Odyssey infra-red scanner (LI-COR, Lincoln, NE, USA). To control for unwanted sources of variation, the relative expression of target proteins in different groups was normalized to β-actin, and the phosphorylation level of target proteins was compared with their total level. The mean values of the control group were set to 1; the values of other groups were normalized to control group values, presented as fold of control values.
Quantitative reverse transcription PCR (qRT-PCR) mRNA transcripts were analysed by qRT-PCR in the PACs or pancreatic tissues. Total RNA was isolated using Trizol reagent (Invitrogen, CA, USA). RNA was subjected to reverse transcription using a commercial SuperScript II preamplification kit (Fermentas, MD, USA); the purity of RNA products was determined by 260/280 ratio to be between 1.8 and 2.0. The synthesized cDNA was then subjected to qRT-PCR using gene-specific, intron-spanning primers (Supporting Information Table S1 ). All the procedures were performed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, CA, USA). To control for unwanted sources of variation, the mRNA levels were normalized to β-actin mRNA, and the fold changes for each mRNA were calculated using the comparative CT (2 ÀΔΔCT ) method. The mean values of the control group were set to 1; the values of other groups were normalized to control group values and presented as fold of control values. Each target gene was analysed in triplicate in each experiment.
Electrophoretic mobility shift assays (EMSAs)
EMSAs were used to check on the binding activity of NF-κB. Nuclear extracts were prepared. A biotin end-labelled probe containing the binding site of NF-κB was incubated with 10 μg nuclear extracts for 30 min at room temperature. Protein-DNA complexes were separated on a native polyacrylamide gel in 0.5× Tris Buffer EDTA and transferred to a positively charged nylon membrane. The biotin end-labelled DNA was detected using a chemiluminescent detection kit.
Preparation of macrophages and neutrophils
Bone marrow-derived macrophages and neutrophils were collected from Balb/C mice as previously described (Weischenfeldt and Porse, 2008; Swamydas and Lionakis, 2013) . Briefly, bone marrow cells were collected from femurs and tibias, red blood cells were removed and resuspended in DMEM F-12 medium supplemented with 10% FBS and 20 ng·mL À1 M-CSF. The cell viability was assessed by the Trypan blue exclusion assay (Gibco, USA) for >95%. To obtain macrophages, aliquots of 1 × 10 6 cells were incubated in 6-well plates, nonadherent cells were removed on day 3 and the cells were continuously cultured with fresh medium until day 7, when the medium was replaced again. On day 8, CD11b and F4/80 positive cells were evaluated by flow cytometry (FACSCaliber, BD Biosciences, Franklin, NJ, USA). Density gradient centrifugation method was used to acquire neutrophils: bone marrow cell suspension was overlaid on the top of the Histopaque 1119/1077 and centrifuged at 400× g for 30 min, and neutrophils at the interface of the Histopaque 1119/1077 layers were collected, then CD11b
and Ly6G positive cells were evaluated by flow cytometry (FACSCaliber, BD Biosciences, Franklin, NJ, USA). Only cell preparations that exhibited 80% or more neutrophils were studied further. For macrophages, PACs were incubated with 10% FBS in the lower chamber, stimulated by 200 nM CCK and treated with quinpirole (2.5, 5 and 10 μM) with or without okadaic acid (2 nM); macrophages were placed in the upper chamber with 0.1% BSA for 6 h. The migration of nonadherent neutrophils was analysed by a Transwell plate (5 μm polycarbonate membrane; Costar, WA, USA) under the stimulation of filtered supernatants of PACs for 30 min. Supernatants of PACs were generated by stimulation of 200 nM CCK and treatment with quinpirole at 2.5, 5 and 10 μM with or without okadaic acid at 2 nM for 6 h. Cell migration was detected by crystal violet staining, and the neutrophils suspended in the lower chamber were also counted. The concentrations of CCL2 and CXCL2 in the supernatants of the cultured PACs were measured by ELISA.
To control for unwanted sources of variation, the mean migration (cell number) of the control group was set to 1. The values of other groups were normalized to control group values, presented as fold of control values.
Statistical analysis
All data are presented as mean ± SEM. The distribution of data was assessed by Kolmogorov-Smirnov test at first. If data followed a Gaussian distribution, parametric tests (Student's t-test for two groups, or one-way ANOVA for three or more groups) were carried out; for ANOVA, Bonferroni's post test was performed for data with F at P < 0.05 and no significant variance inhomogeneity. If data were not normally distributed, non-parametric tests (Mann-Whitney test for two groups or Kruskal-Wallis test with Dunn's post test for three or more groups) were used by GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla, CA, USA, www. graphpad.com). A P value <0.05 was considered statistically significant. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . The results were obtained from at least three independent experiments, with six mice (n = 6) per group to ensure their reliability.
Materials
Caerulein (#AS-24252) was purchased from Anaspec (Fremont, CA, USA). L-Arginine monohydrochloride (L-Arg; A5131), LPS (#L2880), quinpirole (#Q102), SCH (#D054), eticlopride (#E101) and okadaic acid (#O8010) were purchased from Sigma-Aldrich Chemical (St. Louis, MO, USA). BSA was purchased from Roche (Basel, Switzerland). Antibodies against DDC (#sc-99203), DBH (#sc-15318), MAO (#sc-20156) , DRD2 (#sc-7523) and amylase (#sc-46657) were from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies against tyrosine hydroxylase (TH; #2792), PI3K (#4257), phosphorylated PI3K (#4228), Akt (#4691), phosphorylated Akt (#13038), phosphorylated IKK (#2697), IκBα (#4812), phosphorylated IκBα (#2859), NF-κBp65 (#8242), phosphorylated NF-κBp65 (#3033) and PP2A-C (#2259) were from Cell Signaling Technology (Danvers, MA, USA). Antibodies against DRD1 (#ab20066) and Ly6G (#ab25377) were from Abcam (Cambridge, MA, USA). Antibodies against IKK (#15649-1-AP), TNF-α (#60291-1-Ig) and BJP X Han et al.
IL-1β (#16806-1-AP) were from Proteintech Biotechnology (Wuhan, China). Antibody against PPP2R2C (#NBP1-69160) was purchased from Novus Biologicals (Littleton, CO, USA). Antibody against IL-6 (#BS6419) was from Bioworld Technology (St. Louis Park, MN, USA), and antibody against β-actin (#AF0003) was purchased from Beyotime Biotechnology (Shanghai, China). Antibody against F4/80 (#GTX26640) was from GeneTex (San Antonio, TX, USA). PE-conjugated rat antimouse F4/80 antibody (#565410), PE-conjugated rat anti-mouse Ly6G antibody (#551461) and FITC-conjugated rat anti-mouse CD11b antibody (#561688) were purchased from BD Biosciences (Franklin, NJ, USA). Nuclear and Cytoplasmic Extraction Reagents was from Pierce (Rockford, IL, USA). The biotin-labelled probe containing the NF-κB consensus site was purchased from Beyotime Biotechnology. The Light Shift chemilumines-cent EMSA kit was from Pierce. Transwell chamber was from Corning (NY, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharma cology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
The pancreas dopaminergic system is activated, but expression of D 1 and D 2 receptors are decreased in experimental pancreatitis
As shown in Figure 1 , the dopamine level was elevated in human serum of severe AP patients compared to healthy people and those with mild AP ( Figure 1A) , and the serum levels of dopamine were significantly elevated at 12 h following caerulein-and LPS-induced experimental pancreatitis ( Figure 1B, C) , suggesting the dopaminergic system is activated after AP. To test whether the pancreatic dopaminergic system is also activated in AP, we examined the levels of pancreatic dopamine synthetase and metabolism enzymes in AP. From in vitro samples and those from the two models of AP in vivo ( Figure 1C , D and Supporting Information Figure S1A ), Western blot analyses showed that protein levels of the pancreatic dopamine synthetase (TH and DDC) and metabolism enzymes (DBH and MAO) were significantly increased ( Figure 1E ), whereas D 1 and D 2 receptors were decreased ( Figure 1F and Supporting Information Figure S1B , C). Among the five dopamine receptors, the expressions of D 1 and D 2 receptors were significantly reduced at 6-12 h in caerulein-and LPS-induced AP in vivo or at 4 h after stimulation by CCK in vitro (Supporting Information Figure S1B -E), the time at which the inflammation was most obvious (Supporting Information Figure S1A ). D 2 receptors were reduced more obviously in the L-arginine-induce model of AP than in caerulein-and LPS-induced AP ( Figure 1F ). Histological analysis revealed that AP is a self-resolving process during caerulein-and LPS-induced pancreatitis. Acute inflammation increased gradually from 12-24 h and was then restored within 5-7 days (Supporting Information Figure S1A ). D 1 and D 2 levels increased progressively and had returned to a normal level as the inflammation disappeared (Supporting Information Figure S1B , C). Serum dopamine reached a peak level at 6-12 h and reduced gradually to normal level until day5 (Supporting Information Figure S1F ). These results suggest that dopamine signalling might serve as an endogenous protective regulator of pancreatitis; however, down-regulation of D receptors may limit the protective effects of dopamine on AP.
Dopamine signalling inhibits NF-κB activation via D 2 receptors in experimental pancreatitis
As shown in Figure 2 , qRT-PCR and Western blot analyses revealed that dopamine reduced CCK-induced increased expression of inflammatory cytokines (TNFα, IL-1β and IL-6) by inhibiting the IκBα/NF-κB signalling pathway in a dosedependent manner in vitro (Figure 2A, B) . Of note, we also found that dopamine can up-regulate the expression of D 1 and D 2 receptor mRNA and protein levels (Supporting Information Figure S2 ). These results show that dopamine signalling has an anti-inflammatory effect on AP through inhibiting NF-κB activation via its modulation of D 1 or D 2 receptors. Next, we investigated the mechanisms underlying the anti-inflammatory effect of dopamine on AP. Dopamine exerts its effects by binding to its receptors located on the surface of cells. There is evidence indicating that stimulation of low-affinity dopamine receptors, including D 1 and D 2 , is coupled to anti-inflammatory mechanisms (Wei et al., 2013; Yan et al., 2015) . To determine which receptor was involved in the inhibitory effect of dopamine on NF-κB, the D 1 antagonist (SCH) and D 2 antagonist (eticlopride) were administered in the in vivo and in vitro model of AP ( Figure 2C ). The severity of experimental pancreatitis was evaluated by measuring the levels of amylase and lipase in the serum. Morphological evidence of the extent of the pancreatic injury was obtained by standard histological examination. As shown in Figure 2 , eticlopride significantly suppressed the anti-inflammatory effect of dopamine on AP, while SCH had no effect ( Figure 2D-F) . Furthermore, we also found that eticlopride markedly blocked the reduction of IκBα, NF-κBp65 phosphorylation levels, TNFα, IL-1β and IL-6 protein and mRNA levels induced by dopamine both in vivo ( Figure 3A , B) and in vitro ( Figure 3C, D) , while SCH had no effect. Therefore, a D 2 antagonist, but not a D 1 antagonist, can block the inhibitory effect of dopamine on the NF-κB pathway. These data showed that dopamine ameliorated experimental AP in mice through inhibition of NF-κB activation via the D 2 receptor signalling pathway. D 2 receptor activation exerts an anti-inflammatory effect through inhibiting NF-κB activation in experimental pancreatitis
To determine the role of the D 2 receptor signalling pathway on AP, a D 2 agonist (quinpirole) was administered before caerulein and LPS or CCK challenge, dopamine was administered at the same time as caerulein. As shown in Figure 4A -C, markedly decreased amylase and lipase activities were observed in the sera of quinpirole-or dopamine-treated mice at 12 h after the first caerulein injection ( Figure 4C ). In addition, histological examination of the pancreas showed that the extent of pancreatic injury in quinpirole-or dopamine-treated mice was less severe than that in mice treated with vehicle ( Figure 4A, B) . Furthermore, we found that both quinpirole and dopamine reduced IκBα and NF-κ Bp65 phosphorylation, NF-κB binding activity and TNFα, IL- . *n = 6 per group. Cae, caerulein; NC, normal control. Scale bar = 100 μm. *P < 0.05 versus NC, # P < 0.05 versus AP or CCK and + P < 0.05 versus dopamine.
1β and IL-6 levels in caerulein-and LPS-induced pancreatitis ( Figure 4D , E) and CCK-stimulated PACs ( Figure 4F -H).
Experimental pancreatitis aggravated in pancreas-specific Drd2 À/À mice Next, to determine whether the pancreatic dopaminergic system regulates inflammation in AP, we crossed Drd2 fl/fl mice with Pdx1 +/Cre mice to generate pancreas-specific Pdx1 +/Cre / Drd2 fl/fl (Drd2 À/À ) mice (Supporting Information Figure S3 ).
Histological analysis showed that pancreatic injury in Drd2 À/À mice was more severe than that in the WT group ( Figure 5A ). Loss of Drd2 in the pancreas led to a significant enhancement of caerulein-and LPS-induced Akt, IKKα, IκBα and NF-κBp65 phosphorylation but not PI3K ( Figure 5B ). In parallel, loss of Drd2 in the pancreas led to a significant enhancement of caerulein-and LPS-induced intro-pancreatic cytokines (TNFα, IL-1β and IL-6) and chemokines (CCL2 and CXCL2) expression ( Figure 5C, D) . In addition, the serum levels of TNFα, IL-1β, IL-6, CCL2 and CXCL2 were significantly increased at 12 h in the Drd2 À/À mice when compared with the WT mice after administration of caerulein and LPS ( Figure 5E ). The macrophage marker F4/80 and neutrophil marker Ly6G analyses revealed that the number of macrophages and neutrophils in the pancreas were significantly enhanced in the AP in Drd2 À/À compared to those in WT mice ( Figure 5F ). Loss of Drd2 also aggravated lung injury and increased neutrophil infiltration in lung during AP ( Figure 5G ). These data indicate that the pancreas-specific Drd2 deficiency resulted in an enhanced local and systemic inflammatory response via the Akt/NF-κB signalling pathway.
D 2 receptor signalling inhibits NF-κB activation via PP2A-dependent Akt signalling pathway in experimental pancreatitis
Next, we determined how dopamine and D 2 receptor signalling inhibits NF-κB activation. As shown in the above results, we found that dopamine and D 2 receptor signalling inhibits NF-κB activation by reducing p-IκBα. IκBα phosphorylation is triggered by activation of the IκB kinase (IKK) complex, through serine/threonine kinase (Akt). Akt is a major downstream target of PI3K and is rigorously modulated by PI3K (Rommel et al., 2007) . Firstly, we found that CCK stimulation significantly increased PI3K, Akt and IKK phosphorylation with a peak at 15 min, which then gradually declined until 120 min (Supporting Information Figure S4A ), while IκBα and NF-κBp65 phosphorylation were increased with a peak at 30-60 min and decreased until 4 h (Supporting Information Figure S4B ). To test whether D 2 receptor signalling inhibits NF-κB activation via the PI3K/Akt/IKK signalling pathway, we investigated the effect of the D 2 agonist quinpirole on PI3K, Akt and IKK phosphorylation in AP. PACs were treated with quinpirole at the indicated time of CCK stimulation. PI3K, Akt and IKK phosphorylation were detected at 15 min, IκBα and NF-κBp65 phosphorylation at 1 h and TNFα, IL-1β and IL-6 at 4 h. We found that quinpirole markedly decreased the phosphorylation of Akt, IKKα, IκBα and NF-κBp65, but not PI3K (Supporting Information Figure  S5A ). The mRNA and protein levels of TNFα, IL-1β and IL-6 were reduced by quinpirole in a dose-dependent manner (Supporting Information Figure S5B , C). These results show that D 2 receptor signalling inhibits NF-κB activation via the Akt signalling pathway independently of PI3K. Akt inactivation is regulated by PP2A, which is a major serine/threonine phosphatase and modulates the activity of various protein kinases such as Akt (Millward et al., 1999) . PP2A is comprised of three subunits: a scaffold subunit (A), regulatory subunit (B) and catalytic subunit (C) (Millward et al., 1999; Andrabi et al., 2007) . To test whether PP2A regulates Akt in AP, we examined the expression of the regulatory subunit (PP2A-B or PPP2R2C) and catalytic subunit (PP2A-C) of PP2A. Quinpirole increased significantly PPP2R2C expression in a time-dependent manner both in vitro and in vivo. In vitro, quinpirole-treated PACs showed an increased expression of PPP2R2C with a peak at 15 min, but not PP2A-C; in vivo, PPP2R2C expression in the pancreas was significantly increased at 12 h after quinpirole administration, while PP2A-C showed no change ( Figure 6A ). PPP2R2C expression was down-regulated in CCK-stimulated PACs or caerulein-and LPS-induced or L-arginine-induced pancreatitis and up-regulated by quinpirole. In addition, PPP2R2C expression was markedly decreased in Drd2 À/À mice ( Figure 7D ). To determine whether the effects of quinpirole were regulated by PP2A, we pretreated PACs or mice with a selective PP2A inhibitor, okadaic acid ( Figure 7A, B) . As shown in Figures 6 and 7 , okadaic acid reversed the inhibitory activity of quinpirole on Akt, IKKα, IκBα and NF-κBp65 phosphorylation, NF-κB binding activity and TNFα, IL-1β and IL-6 levels in CCK-stimulated PACs ( Figure 6B-E) . Okadaic acid also reversed the protective effects of quinpirole on AP: assessed by evaluating histology of pancreas ( Figure 7C ). Okadaic acid reversed not only the inhibitory role of quinpirole on macrophage and neutrophil migration in the pancreas but also lung injury and neutrophil infiltration in the lung of caerulein-and LPS-induced AP ( Figure 7E, F) . Furthermore, okadaic acid reversed the inhibitory activity of quinpirole on Akt, IKKα, IκBα and NF-κBp65 phosphorylation, mRNA and protein levels of TNFα, IL-1β and IL-6 in both AP models in vivo (Figure 8 ). Taken together, these results showed that D 2 receptor signalling inhibits NF-κB activation via a PP2A-dependent Akt signalling pathway in AP.
D 2 receptor signalling inhibits macrophage and neutrophil migration by reducing CCL2 and CXCL2 expression in vitro
As shown in Figure 9 , quinpirole significantly reduced the levels of CCL2 and CXCL2 mRNA and protein levels in CCK-stimulated PACs ( Figure 9A , B, F, G). It has been reported that CCL2 and CXCL2 can induce macrophage and neutrophil migration in caerulein-induced pancreatitis in mice (Keck et al., 2002; Saeki et al., 2012) . To test whether quinpirole can inhibit macrophage and neutrophil migration, we acquired bone marrow-derived macrophages and neutrophils, whose purity were 90.23 and 85.03% ( Figure 9C , H). They were then incubated with PACs or PACs' medium in a Transwell co-culture system respectively. We found that macrophage and neutrophil migration significantly increased in the CCK-stimulated group and decreased in the quinpirole-treated group in a dose-dependent manner at 6 h and 30 min respectively ( Figure 9D , E, I, J). Furthermore, we found that okadaic acid reversed the inhibitory effect of quinpirole on the up-regulation of CCL2 and CXCL2 induced by caerulein and LPS in the pancreas or CCK in PACs ( Figure 10A , B, D, E). Similarly, okadaic acid also reversed the inhibitory effect of quinpirole on the migration of macrophages ( Figure 10C ) and neutrophils ( Figure 10F ) in CCK-stimulated PACs. These results suggest that quinpirole inhibits macrophage and neutrophil migration by reducing CCL2 and CXCL2 expression via a PP2A-dependent Akt/NF-κB signalling pathway. Taken together, all these data indicate that in the pancreas D 2 receptor signalling inhibits local and systemic inflammatory responses via a PP2A-dependent Akt/NF-κB signalling pathway ( Figure 10G ).
Discussion and conclusions
Increasing evidence has shown that dopamine can function as a local chemical messenger in several periphery organs of the body, besides being a neurotransmitter in the brain (Beaulieu and Gainetdinov, 2011) . Although a substantial (Mckenna et al., 2002) . Previous studies have reported that human pancreatic islet cells express dopamine receptors and dopamine can influence the secretion of insulin (Rubí et al., 2005; Piston, 2013; Zhang et al., 2015c) . Here, we showed for the first time that dopamine receptors are also expressed in PACs. Mezey and colleagues demonstrated that dopamine itself as well as TH is present in exocrine pancreatic cells by immunocytochemistry. Consistent with this, our results demonstrate that both of dopamine synthesizing (TH and DDC) and metabolism enzymes (DBH and MAO) exist in murine exocrine pancreas. These results suggest that the acinar cell itself can produce dopamine from circulating L-dopa, which has not been reported previously. The dopamine level was elevated in human serum of AP patients compared to healthy people. Thus, dopamine may act on the pancreas via autocrine or paracrine pathways. Of note, although the pancreas dopaminergic system is activated, D 1 and D 2 receptor levels were significantly decreased in the in vivo and in vitro model of experimental pancreatitis, suggesting a down-regulation of these receptors limits the protective effects of dopamine during AP. Moreover, we found that D 1 and D 2 receptor levels were restored to normal levels as the inflammation subsided in the caerulein-and LPS-or L-arginine-induced pancreatitis in mice. Taken together, these results indicate that dopamine signalling may be an endogenous inhibitor of inflammation in AP, which encouraged us to further explore the role of dopamine signalling in AP. Previous studies showed that dopamine is an effective treatment for experimental AP, as a result of the reduction in pancreatic microvascular permeability and inflammatory cytokines (Karanjia et al., 1991; 1994; Zhang et al., 2007) . However, Kaya indicated that a low dose of dopamine attenuates the lung injury but not the local pancreatic injury in 5% Na-taurocolic acid-induced AP in rats (Kaya et al., 2005) . This may be due to variations in the different AP models and the timing of the observations. We improved the administration method of dopamine, injecting it i.p. at the same time as caerulein ,10 times separately, which takes into account its short half-life (Zaroslinski et al., 1977) . Therefore, our data showed that dopamine can attenuate experimental pancreatitis by inhibiting the NF-κB signalling pathway. Recently, Yan and colleagues demonstrated that D 1 receptor signalling can control the processing and secretion of IL-1β and IL-18 in both systemic and periphery inflammation by inhibiting the NLRP3 inflammasome (Yan et al., 2015) . In addition, Shao and colleagues indicated that astrocytic D 2 receptor activation could suppress neuroinflammation in the CNS through a CRYAB-dependent mechanism (Wei et al., 2013) . D 1 and D 2 agonists may act through different pathways. D 1 receptor signalling can inhibit NLRP3 inflammasome activation via cAMP, while D 2 receptor signalling can inhibit the NF-κB signalling pathway that then results in a reduction in NLRP3 mRNA expression (Vande et al., 2014; Yan et al., 2015; Zhang et al., 2015a) . In addition, Hoque and colleagues showed that NF-κB regulates the mRNA expression of NLRP3, which can form the NLRP3 inflammasome (Hoque et al., 2011) . Both NF-κB and inflammasome are involved in the pathophysiological process of AP, and NF-κB can regulate NLRP3 inflammasome; therefore, either D 1 or D 2 receptor activation can ameliorate AP via NF-κB inhibition theoretically (Hoque et al., 2011; Huang et al., 2013) . However, we found that a D 2 antagonist but not a D 1 antagonist blocked the protective effects of dopamine on AP. The reason for this result is explained by the following findings. Gene chips of the L-arginine murine model showed that the D 2 receptor expression level was over three times that of D 1 receptors in normal pancreas and 25 times more in AP (data not shown). Because both D 1 and D 2 receptors are low-affinity receptors, we speculate that dopamine may mainly combine with D 2 receptors in AP. It was reported that Drd2 À/À mice exhibited spontaneous inflammation in the brain and activation of D 2 receptors can suppress levels of pro-inflammatory cytokines, including TNF-α (Wei et al., 2013) . Therefore, a D 2 antagonist may block the inhibitory effects of dopamine on inflammatory cytokines via NF-κB, but we cannot exclude the possibility of a subsequent D 2 receptor-mediated effect on inflammasome activation in AP. Taken together, these results indicate that dopamine can negatively regulate NF-κB activation via D 2 receptor signalling in AP, suggesting that D 2 receptors might be a potential target for treatment of AP. Furthermore, we found that D 2 receptor signalling inhibits NF-κB activation via Akt signalling pathway independently of PI3K in AP. PI3K can positively regulate Akt inactivation, whereas Akt inactivation is regulated by PP2A, which is a major serine/threonine phosphatase and modulates the activity of various protein kinases such as Akt (Millward et al., 1999; Matsuoka et al., 2003) . PP2A consists of a family of heterotrimers composed of one scaffolding (A), one catalytic (C) and one regulatory (B) subunit and is expressed in the pancreas (Millward et al., 1999; Andrabi et al., 2007; Sandoval et al., 2009) . There are several regulatory B subunits, of which PPP2R2C, a γ isoform of the subunit B55 subfamily, has been reported to associate with Akt selectively, regulating phosphorylation of Akt at Thr 308 (Kuo et al., 2008; Zhang et al., 2015b) . Of note, PP2A is oxidized and inactive in AP (Kuo et al., 2008; Sandoval et al., 2009) . Consistent with these findings, our results indicate that Akt phosphorylation is increased, but PP2A expression is decreased in AP. Moreover, we also found that D 2 receptor activation could partly increase the expression of PPP2R2C, which leads to Akt dephosphorylation, and then inhibits the IKKα/IκBα/NF-κB signalling pathway. In addition, we found that the PP2A antagonist okadaic acid reversed the protective effects of a D 2 agonist on AP. More importantly, compared to WT mice, pancreas-specific Drd2 À/À mice exhibited a more severe AP, along with less PPP2R2C expression and more Akt/IKK/ IκBα/NF-κB phosphorylation and intense local and systemic inflammatory response. Taken together, these results indicate that the protective effects of D 2 receptors on AP were exerted at least in part through the inhibition of Akt phosphorylation via PP2A. This phenomenon was similar to that in mouse renal proximal tubule cells: the D 2 receptor controls renal inflammation, at least in part by modulation of Akt pathway through PP2A (Zhang et al., 2015b) . As to the changes in the other signalling pathways or trypsinogen activation or necrosis after Drd2 knockout, further studies need to be undertaken. AP is characterized by trypsinogen activation and an infiltration of immune cells into the pancreas (Pandol et al., 2007) . The earliest events in AP occur within acinar cells, but macrophages and neutrophils can worsen the pancreatic injury and lead to SIRS (Shrivastava and Bhatia, 2010; Xue et al., 2014; Yang et al., 2015) . Accumulating evidence indicates that PACs can produce CCL2 and CXCL2 and NF-κ B is involved in the induction of many pro-inflammatory mediators (Panahi et al., 2015; Steele et al., 2015) . As monocytes express the CCL2 receptor, CCR2, and neutrophils express the CXCL2 receptor, CXCR2, the chemokines produced by PACs can promote the migration and accumulation of macrophages and neutrophils to the pancreas to further magnify the inflammatory response (Feng et al., 1995; Ohtsuka et al., 2001; Terashima et al., 2005; Awla et al., 2011; Saeki et al., 2012; Panahi et al., 2015; Steele et al., 2015) . Consistent with this, we found that CCL2 and CXCL2 expression are up-regulated in both our in vivo and in vitro models of AP. Furthermore, our data show that a D 2 agonist can inhibit the up-regulation of CCL2 and CXCL2 and macrophage and neutrophil migration in vitro, while the PP2A inhibitor okadaic acid attenuated the inhibitory effects of quinpirole on the secretion of chemokines and migration of immune cells. Furthermore, pancreas-specific Drd2 À/À mice had an increased infiltration of inflammatory cells compared to WT mice with AP. Taken together, these results indicate that D 2 receptor signalling in the pancreas inhibits macrophage and neutrophil migration by reducing CCL2 and CXCL2 expression from PACs via a PP2A-dependent Akt/NF-κB signalling pathway. Because dopamine and its agonists has been shown to have an effect on immune cells including macrophages, we cannot exclude the possibility that the activation of D 2 receptors has a direct inhibitory effect on immune cells in AP (Yan et al., 2015) . Although we demonstrated the protective role of D 2 receptors on PACs in vitro and in vivo via both WT and pancreas-specific Drd2 À/À mice, the role of the dopaminergic system on effects on other cells such as macrophages and neutrophils in AP needs to be further clarified. In summary, as presented in Figure 10G , in this study we have shown that in experimental pancreatitis, the pancreas dopaminergic system is activated, but D 1 and D 2 receptors are decreased. However, D 2 receptor signalling controls pancreatic inflammation in AP at least in part through inhibiting NF-κB signalling via a PP2A-dependent Akt pathway. Further insights into the mechanisms through which the inflammatory pathways are activated may hold the key to increase our understanding of pancreatitis. Moreover, therapeutic approaches that activate D 2 receptor signalling may represent a novel strategy for preventing or attenuating inflammation in AP clinically.
